Compounds and anti-tumor NQO1 substrates

US9925180B2 · kind B2 · utility

Assignees

• The Board of Trustees of the University of Illinois · US
• The Board of Regents of the University of Texas System · US

Inventors

• Paul J. Hergenrother · Champaign, US
• David Boothman · Dallas, US
• Joseph S. Bair · Albany, US
• Rahul Palchaudhuri · Cambridge, US
• Elizabeth I. Parkinson · Champaign, US

Key dates

• Filing date: Mar 9, 2017
• Grant date: Mar 27, 2018
• Expiry date: Mar 9, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H15/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.